Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer.
Neeb A, Figueiredo I, Bogdan D, Cato L, Stober J, Jiménez-Vacas JM, Gourain V, Lee II, Seeger R, Muhle-Goll C, Gurel B, Welti J, Nava Rodrigues D, Rekowski J, Qiu X, Jiang Y, Di Micco P, Mateos B, Bielskutė S, Riisnaes R, Ferreira A, Miranda S, Crespo M, Buroni L, Ning J, Carreira S, Bräse S, Jung N, Gräßle S, Swain A, Salvatella X, Plymate SR, Al-Lazikani B, Long HW, Yuan W, Brown M, Cato ACB, de Bono JS, Sharp A.
Neeb A, et al. Among authors: sharp a.
Mol Cancer Ther. 2024 Feb 27. doi: 10.1158/1535-7163.MCT-23-0354. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 38412481